The latest developments from suppliers of ingredients, development and manufacturing services, and related technologies for pharmaceutical and biopharmaceutical development and production.
WuXi Biologics, a contract biologics manufacturer, has signed a letter of intent for a strategic partnership with an unnamed vaccine maker for a 20-year supply contract, estimated to be worth more than $3 billion. Under the letter of intent, WuXi...
Catalent has completed its $1.2-billion acquisition of Paragon Bioservices, a contract provider of viral vector development and manufacturing services for gene therapies.
Paragon has development and manufacturing capabilities in adeno-associated...
The latest news from CDMOs, CMOs, and suppliers, featuring news from Fujifilm Diosynth Biotechnologies and Recipharma.
Biologics manufacturing
Fujifilm Diosynth Biotechnologies to Expand UK Site with New BioCampus
Fujifilm Diosynth...
WuXi Biologics, a contract biologics manufacturer, has begun construction of 1.3-million square foot manufacturing center in Chengdu, China, in southwest China.
The new integrated manufacturing center will include drug development and commercial...
Thermo Fisher Scientific has agreed to acquire a drug-substance manufacturing site in Cork, Ireland, from GlaxoSmithKline for approximately EUR 90 million ($100.6 million). Thermo says it will expand capacity at the Cork site for the development...
Catalent has announced it is investing up to $40 million at its manufacturing facility in Winchester, Kentucky to increase the site’s formulation and controlled-release tablet and capsule manufacturing capabilities and capacity.
New technologies...
The latest news from CDMOs, CMOs, and suppliers featuring news from Vetter, Catalent, Cambrex, Sharp and Biotechpharma.
Chemicals/Chemical API Manufacturing
Cambrex Completes Construction for High-Potency API Facility and QC Lab...
Catalent has agreed to acquire Paragon Bioservices, a Baltimore, Maryland-based contract provider of viral vector development and manufacturing services for gene therapies, for $1.2 billion.
Paragon has specialized expertise in adeno-associated...
The latest news from CDMOs, CMOS, and other suppliers featuring news from Wilmington PharmaTech, Insilico, ACG Group, Lonza
Chemicals/Chemical API Manufacturing
Wilmington PharmaTech To Invest $18 Million In New Research and Mfg Facility...
GE has entered into a definitive agreement to sell its BioPharma business to Danaher Corporation, a global science and technology company, headquartered in Washington D.C., for a total consideration of $21.4 billion, including $21 billion in cash...
The latest news from CDMOs, CMOS, and other suppliers featuring news from Charkit, Thermo Fisher Scientific Pharma Services, MilliporeSigma, Charles Rivers, Ompi, and LabVantage.
Chemicals/Chemical API Manufacturing
Charkit Chemical Names New...
The latest news from contract development and manufacturing organizations, contract manufacturing organizations, and other suppliers featuring news from Cerbios-Pharma, Olon, Hovione, Thermo Fisher, GE Healthcare Life Sciences, and PCI Pharma...
Hitachi Chemical, a Tokyo-based chemicals and industrial manufacturer, has agreed to acquire Apceth Biopharma, a Munich, Germany-based contract development and manufacturing organization (CDMO) of cell and gene therapies, for EUR 75.5 million...
A roundup of news from suppliers, contract development and manufacturing organizations (CDMOs), and contract manufacturing organizations (CMOs), featuring developments from Almac, Pii, PCI Pharma Services, MedPharm, and Thousand Oaks...
Boehringer Ingelheim has initiated a capacity expansion in its biopharmaceutical contract manufacturing business at its commercial manufacturing site for biologics in China. The expansion covers an additional bioreactor and includes all needed...
